WuXi Biologics Secures FDA PLI Approval for Five Facilities, First for Commercial PFS Line

• WuXi Biologics' pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-quality PFS solutions to clients worldwide
• Reinforces WuXi Biologics' strong track record of a 100% success rate passing PLIs across our facilities

WUXI, China, July 22, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that five manufacturing facilities successfully passed the Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA), with no critical issues or data integrity findings. This achievement further affirms WuXi Biologics' strong track record of regulatory compliance—a 100% success rate passing PLIs.

The FDA's inspection covered WuXi Biologics' quality management system and the entire production processes of multiple facilities, including two drug substance facilities (MFG1 and MFG5) and three drug product facilities (DP1, DP2 and DP5) in Wuxi, China.  Passing the initial regulatory inspection by the FDA for DP5, the company's first commercial pre-filled syringes (PFS) manufacturing facility, will allow WuXi Biologics to provide high-quality PFS manufacturing solutions to clients.

As of late 2024, WuXi Biologics has successfully passed 42 regulatory inspections, including 22 by the EU EMA and the FDA. Additionally, the company has received 97 license approvals from regulatory agencies around the world.

Dr. Chris Chen, CEO of WuXi Biologics, commented: "At WuXi Biologics, our unwavering commitment to the highest global quality standards is embedded in everything we do. Maintaining a 100% success rate for regulatory inspections is a true reflection of our relentless pursuit of excellence in building a world-class quality system that not only meets but exceeds global regulatory requirements. WuXi Biologics will continue—with speed and efficiency—to enable global partners in delivering life-saving treatments, with the ultimate goal of benefiting patients worldwide."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.